benefits and risks of medicinal products through various forms of evidence, including RWE.

ICH E9 (R1) – Provides principles on the use of estimands and sensitivity analyses in clinical trials, extending into the realm of RWE where longitudinal observational data may provide valuable insights.

Guideline on the use of real-world evidence (draft) – This guideline outlines expectations for generating and utilizing RWE within regulatory submissions, potentially influencing drug approval pathways.

Documentation

Preparing comprehensive documentation is critical for RM submissions involving RWE. It is essential for Regulatory Affairs, CMC, and Labelling teams to ensure the following elements are meticulously addressed:

1. RWE Source Description

Detail the sources of RWE used to support submissions, specifying their relevance and reliability.

2. Analytical Methods

Clearly describe the analytical methods employed to process RWE, including statistical models and validation of data sets.

3. Integration with Clinical Data

Justify how RWE complements traditional clinical data, addressing potential biases and limitations entirely.

4. Regulatory Formats

Adhere to specific submission formats required by the EMA, ensuring compliance with the Common Technical Document (CTD) requirements, particularly Module 1 where RWE is discussed.

Review/Approval Flow

The flow of review and approval concerning submissions incorporating RWE consists of several stages:

1. Pre-submission Consultations: Engage with the EMA early in the development process for guidance on using RWE.
2. Submission of Marketing Authorization Application (MAA): Ensure RWE is clearly integrated into the application, referenced appropriately throughout the documents.
3. Agency Review: Be prepared for questions about the robustness and relevance of the RWE utilized. The agency may request additional data or clarification.
4. Post-Approval Commitments: If approved, be aware that the EMA may impose follow-up studies based on RWE to support long-term safety and efficacy assessment.

Common Deficiencies

Awareness of common pitfalls when submitting RWE data to the EMA is crucial for success:

1. Inadequate Quality of Evidence

Ensure RWE is derived from high-quality, reliable sources. Weak or poorly documented evidence can lead to scrutiny and potential rejection of submissions.

2. Lack of Clarity on Methodology

Insufficient explanations concerning the methodology used to analyze RWE can create confusion. It is important to provide detailed descriptions of analytical approaches applied.

3. Poor Integration with Clinical Evidence

Failing to convincingly integrate RWE with clinical trial data may diminish the submission’s credibility. A clear narrative linking both forms of evidence enhances understanding.

RA-Specific Decision Points

When to File as Variation vs. New Application

Regulatory Affairs professionals need to determine the appropriate filing pathway. If RWE supports a new indication for an existing product, a variation to the existing marketing authorization may be suitable. Conversely, if a completely new product is introduced based on RWE, a new application should be submitted.

How to Justify Bridging Data

In instances where RWE bridges gaps between clinical studies and real-world applications, it’s essential to justify the inclusion of this data:

• Identify Gaps: Clearly outline specific questions or gaps in knowledge that RWE addresses.
• Support with Evidence: Present evidence demonstrating that RWE offers critical insights that bridge these gaps.
• Compliance with Guidelines: Reference relevant guidelines and frameworks that support the use of RWE in your justification.

Agency Expectations

The EMA has established clear expectations concerning RWE submissions:

• Transparency: Provide clear, comprehensive information about the datasets and methodologies employed in the analysis.
• Robustness: Evidence must be rigorous, replicable, and thoroughly validated.
• Relevance: RWE should be pertinent to the target population and indication addressed in the submission.
• Integration: Submissions should seamlessly integrate RWE with traditional clinical data.

Conclusion

In conclusion, the increasing reliance on real-world evidence within the EU regulatory framework, spearheaded by the EMA, is altering the landscape of pharma regulatory affairs. Successful integration of RWE into submissions requires a thorough understanding of the underlying regulations, meticulous documentation processes, and anticipation of agency expectations. By focusing on these areas, Regulatory Affairs professionals can optimize their submissions and navigate the evolving challenges posed by the integration of real-world evidence in pharmacovigilance systems.